4SC (VSC)

Business description

4SC is a Munich-based cancer biopharmaceutical company. Resminostat is the lead candidate for cutaneous T-Cell lymphoma (pivotal study started Q416) and partnered with Yakult Honsha for HCC in Japan. It has a second epigenetic compound, 4SC-202 (planned Phase II H217) and a preclinical asset, 4SC-208. It also partners a Phase I oncology asset.

Stock data

Market cap.€146.5m
Last close€4.78
High / Low (52 weeks)€5.0 / €2.1
Stock market listingDE
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual29.5104.6105.5
Relative *33.497.767.4

* % Relative to local index

Other companies in sector Show

aap Implantate Aastrom Biosciences
AB Science Abcam
Abivax SA Ablynx
Abzena Acarix
Achillion Pharmaceuticals Acorda Therapeutics
Actinium Pharmaceuticals Active Biotech
Acucela Addex Therapeutics
Adherium Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
AFT Pharmaceuticals Agennix
Akari Therapeutics Alchemia
Alexza Pharmaceuticals Algeta
Alimera Sciences ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Allium Medical Solutions
Alnylam Pharmaceuticals Amarantus BioScience
Amarin Amplifon
AmpliPhi Biosciences Angle
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Arix Bioscience Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Ascendis Pharma
Astex Pharmaceuticals Athersys
Atossa Genetics Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Balda
Basilea Pharmaceutica Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences BioLineRx
BiondVax Pharmaceuticals Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio Bone Therapeutics
BrainStorm Cell Therapeutics BTG
C4X Discovery Holdings Can-Fite BioPharma
Capstone Therapeutics Carmat
Cell Therapy Celldex Therapeutics
Cellectis Cellular Biomedicine Group
Celyad Cerulean Pharma
Circadian Technologies Clal Biotechnology
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
co.don AG Collplant Holdings
Consort Medical Corium International
Crescendo Crossject
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
Egalet Corporation EKF Diagnostics
Emergent BioSolutions Endocyte
Epigenomics Erytech Pharma
Esperion Therapeutics Evotec
Exact Sciences Exelixis
Factor Therapeutics Formycon
Forward Pharma Fresenius SE & Co. KGaA
Futura Medical Galapagos
Galmed Pharmaceuticals Genedrive
Genfit Genkyotex
Genmab GeoVax
GI Dynamics Gilead Sciences
GNI Group Ltd GW Pharmaceuticals
Halozyme Therapeutics Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunicum
Immunodiagnostic Systems Holdings Immunovia
ImmuPharma Imprimis Pharmaceuticals
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Intec Pharma
International Stem Cell Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals Kiadis Pharma
Laboratorios Farmacéuticos ROVI LCA-Vision
LeMaitre Vascular Lifeline Scientific
LifeWatch Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene Midatech Pharma
MISSION Therapeutics Molecular Partners
MolMed Mologen
Momenta Pharmaceuticals MorphoSys
Nanobiotix Nanosonics
Navidea Biopharmaceuticals Nektar Therapeutics
NeoStem Neovacs
NetScientific NeuroVive Pharmaceutical
Newron Pharmaceuticals Nexstim
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novacyt
Novogen NPS Pharmaceuticals
Nuevolution Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals Opexa Therapeutics
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
Oryzon Genomics Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
PDL BioPharma Pharmacyclics
PharmaMar Pharmaxis
Pharming Group Photocure
Phylogica Pixium Vision
Pluristem Therapeutics Prescient Therapeutics
Prima BioMed Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences PsiOxus
QRxPharma Quantum Genomics
Quantum Pharmaceuticals RedHill Biopharma
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical Rovi
RXi Pharmaceuticals Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Shire Sierra Oncology
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
Targovax TearLab Corp
Tekmira TESARO
Theraclion Therapix Biosciences
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Titan Pharmaceuticals
Tonix Pharmaceuticals Topotarget
Touchstone Innovations Transgene
Trillium Therapeutics Trimel Pharmaceuticals
TruScreen Ltd TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Wilex
Xbrane Biopharma Xencor
Zafgen Zealand Pharma
Ziopharm Oncology

Company news

Notable Mergers and Acquisitions 7/16: (MGA) (EBAY) (EPD)/(GEL) (AXE)/(HDS)

Thu, 16 Jul 2015 13:58:54 GMT

Evonik to Buy Performance Materials from Air Products (APD) in $3.8B Deal

Fri, 06 May 2016 11:37:30 GMT

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2015A 3.3 (7.9) (8.4) (58.58) N/A N/A
2016A 2.1 (10.9) (10.9) (54.17) N/A N/A
2017E N/A N/A N/A N/A N/A N/A
2018E N/A N/A N/A N/A N/A N/A

Last updated on 17/05/2017

Investment summary

4SC has recently announced an updated and progressive development plan. It has indicated it intends to conduct an equity capital raise to fund the accelerated development of its lead drug candidates. It has initiated (late 2016) its pivotal 150-patient Phase II study with epigenetic compound resminostat (HDAC inhibitor) for cutaneous T-cell lymphoma (CTCL). Top-line data is expected by 2019. Resminostat has also been licensed to Yakult Honsha in Japan (no longer in development with Menarini in the rest of Asia). 4SC announced in 2016 positive Phase II results from a more detailed analysis of the HCC Yakult trial data, which could lead to further clinical development. Alongside resminostat, 4SC intends to advance 4SC-202 into a first pivotal study (late 2018) and complete formal development of 4SC-208 with the aim of starting Phase I/II clinical testing (early 2019). Other ongoing positives include a partnership with Link Health in China for its oncology Eg5 inhibitor, 4SC-205. 4SC held €7.5m in cash Q117.

Last updated on 01/06/2017

Industry outlook

Resminostat could become the first HDAC inhibitor to gain EU approval for CTCL (vs four HDACs approved in the US). CTCL has been validated as a target indication for HDACs, with vorinostat (Merck & Co) and romidepsin (Celgene) FDA-approved on Phase II data.

Last updated on 01/06/2017

Key management

Jason Loveridge, CEO
Dr. Anna Niedl , Manager Corporate Communications and Investor
Wolfgang Güssgen, Head of Corporate Communications and IR

Company address

Am Klopferspitz 19a
82152
Planegg-Martinsried
Germany
+49 (0)89 700763-0
View website